{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T14:31:43Z","timestamp":1783607503995,"version":"3.55.0"},"reference-count":34,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pancreatology"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.pan.2021.06.009","type":"journal-article","created":{"date-parts":[[2021,7,2]],"date-time":"2021-07-02T23:52:30Z","timestamp":1625269950000},"page":"1395-1401","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":48,"title":["Efficacy and safety of rituximab for IgG4-related pancreato-biliary disease: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4522-2921","authenticated-orcid":false,"given":"Marco","family":"Lanzillotta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuel","family":"Della-Torre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachary S.","family":"Wallace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John H.","family":"Stone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3443-3117","authenticated-orcid":false,"given":"Omer","family":"Karadag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreu","family":"Fern\u00e1ndez-Codina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo Giorgio","family":"Arcidiacono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9654-7243","authenticated-orcid":false,"given":"Massimo","family":"Falconi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Dagna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0019-8753","authenticated-orcid":false,"given":"Gabriele","family":"Capurso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pan.2021.06.009_bib1","doi-asserted-by":"crossref","first-page":"m1067","DOI":"10.1136\/bmj.m1067","article-title":"Advances in the diagnosis and management of IgG4 related disease","volume":"369","author":"Lanzillotta","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.pan.2021.06.009_bib2","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1111\/cei.12641","article-title":"Immunology of IgG4-related disease","volume":"181","author":"Della-Torre","year":"2015","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.pan.2021.06.009_bib3","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.ejim.2019.12.029","article-title":"Long-term efficacy of maintenance therapy with Rituximab for IgG4-related disease","volume":"74","author":"Campochiaro","year":"2020","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.pan.2021.06.009_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejim.2020.12.006","article-title":"Efficacy and safety of rituximab biosimilar (CT-P10) in IgG4-related disease: an observational prospective open-label cohort study","author":"Della-Torre","year":"2021","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.pan.2021.06.009_bib5","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1136\/annrheumdis-2014-206605","article-title":"Rituximab for IgG4-related disease: a prospective, open-label trial","volume":"74","author":"Carruthers","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.pan.2021.06.009_bib6","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/j.jaci.2019.07.004","article-title":"B\u00a0lymphocytes directly contribute to tissue fibrosis in patients with IgG 4-related disease","volume":"145","author":"Della-Torre","year":"2020","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.pan.2021.06.009_bib7","doi-asserted-by":"crossref","first-page":"2236","DOI":"10.1136\/annrheumdis-2014-205799","article-title":"B-cell depletion attenuates serological biomarkers of fibrosis and myofibroblast activation in IgG4-related disease","volume":"74","author":"Della-Torre","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.pan.2021.06.009_bib8","article-title":"Mer tyrosine kinase (MerTK) as a possible link between resolution of inflammation and tissue fibrosis in IgG4-related disease","volume":"keab096","author":"Rovati","year":"2021","journal-title":"Rheumatology"},{"key":"10.1016\/j.pan.2021.06.009_bib9","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1002\/art.40469","article-title":"A\u00a0CD8\u03b1- subset of CD4+SLAMF7+ cytotoxic T cells is expanded in patients with IgG4-related disease and decreases following glucocorticoid treatment","volume":"70","author":"Della-Torre","year":"2018","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.pan.2021.06.009_bib10","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1136\/annrheumdis-2018-214603","article-title":"ACR\/EULAR IgG4-RD Classification Criteria Committee. Clinical phenotypes of IgG4-related disease: an analysis of two international cross- sectional cohorts","volume":"78","author":"Wallace","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.pan.2021.06.009_bib11","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.1093\/rheumatology\/keaa221","article-title":"Clinical phenotypes of IgG4-related disease reflect different prognostic outcomes","volume":"59","author":"Lanzillotta","year":"2020","journal-title":"Rheumatology"},{"key":"10.1016\/j.pan.2021.06.009_bib12","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1080\/03009742.2020.1771763","article-title":"Urgent manifestations of immunoglobulin G4-related disease","volume":"50","author":"Della-Torre","year":"2021","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.pan.2021.06.009_bib13","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1136\/annrheumdis-2016-210002","article-title":"Development of a Glucocorticoid Toxicity Index (GTI) using multicriteria decision analysis","volume":"76","author":"Miloslavsky","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.pan.2021.06.009_bib14","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1097\/MPA.0b013e3182142fd2","article-title":"International consensus diagnostic criteria for autoimmune pancreatitis: guidelines of the International Association of Pancreatology","volume":"40","author":"Shimosegawa","year":"2011","journal-title":"Pancreas"},{"key":"10.1016\/j.pan.2021.06.009_bib15","doi-asserted-by":"crossref","first-page":"1010e6","DOI":"10.1016\/j.cgh.2006.05.017","article-title":"Diagnosis of autoimmune pancreatitis: the Mayo Clinic experience","volume":"4","author":"Chari","year":"2006","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.pan.2021.06.009_bib16","doi-asserted-by":"crossref","first-page":"403e8","DOI":"10.1007\/s00535-008-2205-6","article-title":"Asian diagnostic criteria for autoimmune pancreatitis: consensus of the Japan-Korea symposium on autoimmune pancreatitis","volume":"43","author":"Otsuki","year":"2008","journal-title":"J\u00a0Gastroenterol"},{"key":"10.1016\/j.pan.2021.06.009_bib18","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Contr Clin Trials"},{"key":"10.1016\/j.pan.2021.06.009_bib19","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Stat Med"},{"issue":"7109","key":"10.1016\/j.pan.2021.06.009_bib20","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"10.1016\/j.pan.2021.06.009_bib21","doi-asserted-by":"crossref","first-page":"g7647","DOI":"10.1136\/bmj.g7647","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation","volume":"350","author":"Shamseer","year":"2015","journal-title":"BMJ"},{"key":"10.1016\/j.pan.2021.06.009_bib22","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1001\/jama.283.15.2008","article-title":"Meta analysis of observational studies in epidemiology: a proposal for reporting: meta analysis of Observational Studies in Epidemiology (MOOSE) group","volume":"283","author":"Stroup","year":"2000","journal-title":"J\u00a0Am Med Assoc"},{"key":"10.1016\/j.pan.2021.06.009_bib23","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1093\/rheumatology\/kev438","article-title":"Predictors of disease relapse in IgG4-related disease following rituximab","volume":"55","author":"Wallace","year":"2016","journal-title":"Rheumatology"},{"key":"10.1016\/j.pan.2021.06.009_bib24","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.3906\/sag-1704-150","article-title":"The clinical features and outcomes of Turkish patients with IgG4-related disease:a single-center experience","volume":"47","author":"Karada\u011f","year":"2017","journal-title":"Turk J Med Sci"},{"key":"10.1016\/j.pan.2021.06.009_bib25","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.jbspin.2018.01.014","article-title":"Treatment and outcomes in patients with IgG4-related disease using the IgG4 responder index","volume":"85","author":"Fern\u00e1ndez-Codina","year":"2018","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.pan.2021.06.009_bib26","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1016\/j.cgh.2018.02.049","article-title":"Rituximab maintenance therapy reduces rate of relapse of pancreaticobiliary immunoglobulin G4-related disease","volume":"16","author":"Majumder","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.pan.2021.06.009_bib27","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1177\/2050640619862459","article-title":"Risk factors and treatment of relapses in autoimmune pancreatitis: rituximab is safe and effective","volume":"7","author":"Soliman","year":"2019","journal-title":"United European Gastroenterol J"},{"key":"10.1016\/j.pan.2021.06.009_bib28","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.jaci.2020.05.022","article-title":"CD4\u00a0+ and CD8\u00a0+ cytotoxic T lymphocytes may induce mesenchymal cell apoptosis in IgG 4-related disease","volume":"147","author":"Perugino","year":"2021","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.pan.2021.06.009_bib29","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1093\/rheumatology\/kex234","article-title":"Quantitative measurement of 18F-FDG PET\/CT uptake reflects the expansion of circulating plasmablasts in IgG4-related disease","volume":"56","author":"Berti","year":"2017","journal-title":"Rheumatology"},{"issue":"21","key":"10.1016\/j.pan.2021.06.009_bib30","first-page":"S1424","article-title":"Determination of the duration of glucocorticoid therapy in type 1 autoimmune pancreatitis: a systematic review and meta-analysis","author":"Yoon","year":"2021","journal-title":"Pancreatology"},{"key":"10.1016\/j.pan.2021.06.009_bib31","doi-asserted-by":"crossref","first-page":"408","DOI":"10.3389\/fmed.2020.00408","article-title":"PrescrAIP: a pan-European study on current treatment regimens of auto-immune pancreatitis","volume":"7","author":"Lanzillotta","year":"2020","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.pan.2021.06.009_bib32","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1177\/2050640620934911","article-title":"European Guideline on IgG4-related digestive disease - UEG and SGF evidence-based recommendations","volume":"8","author":"L\u00f6hr","year":"2020","journal-title":"United European Gastroenterol J"},{"key":"10.1016\/j.pan.2021.06.009_bib33","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1093\/rheumatology\/key227","article-title":"Efficacy and safety of low dose Mycophenolate mofetil treatment for immunoglobulin G4-related disease: a randomized clinical trial","volume":"58","author":"Yunyun","year":"2019","journal-title":"Rheumatology"},{"key":"10.1016\/j.pan.2021.06.009_bib34","doi-asserted-by":"crossref","first-page":"6195","DOI":"10.1038\/s41598-017-06520-5","article-title":"Efficacy of Cyclophosphamide treatment for immunoglobulin G4-related disease with addition of glucocorticoids","volume":"7","author":"Yunyun","year":"2017","journal-title":"Sci Rep"},{"issue":"8","key":"10.1016\/j.pan.2021.06.009_bib35","doi-asserted-by":"crossref","first-page":"e90","DOI":"10.1038\/ctg.2017.17","article-title":"Azathioprine maintenance therapy to prevent relapses in autoimmune pancreatitis","volume":"27","author":"de Pretis","year":"2017","journal-title":"Clin Transl Gastroenterol"}],"container-title":["Pancreatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1424390321004944?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1424390321004944?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T16:16:34Z","timestamp":1761408994000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1424390321004944"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":34,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["S1424390321004944"],"URL":"https:\/\/doi.org\/10.1016\/j.pan.2021.06.009","relation":{},"ISSN":["1424-3903"],"issn-type":[{"value":"1424-3903","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of rituximab for IgG4-related pancreato-biliary disease: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Pancreatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pan.2021.06.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 IAP and EPC. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}